Cell-Based Assays Keep Biosimilars on Track


David Rusnak, BioAgilytix’s Director of Bioanalytical Operations, contributes to this article by Genetic Engineering & Biotechnology News (GEN) discussing how cell-based assays have become a mainstay of drug development, addressing new concerns raised by the advent of biologics – including the difficulties inherent in characterizing drug efficacy and patient safety in the context of immunogenicity.

Click for full article

Featured Expert

Pharmacokinetics & Pharmacodynamics​

See how our PK expertise complements our immunogenicity services by evaluating absorption, distribution, metabolism and excretion characteristics of a product.
220328 Adleverage_Scientific Icon Illustrations_#46-65_CO_Per FIles